Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Compugen ( (CGEN) ) just unveiled an announcement.
On May 18, 2026, Compugen reported first-quarter 2026 results, highlighting continued execution across its cancer immunotherapy pipeline and progress in key collaborations. The company’s blinded randomized MAIA-ovarian maintenance trial of COM701 in relapsed platinum-sensitive ovarian cancer is actively enrolling in the U.S., Israel and France, with an interim analysis planned once median progression-free survival is reached by the first quarter of 2027.
AstraZeneca is advancing rilvegostomig in 11 Phase 3 trials and showcased clinical and pre-clinical data, including late-breaking Phase 2 results in HER2-positive gastric cancer at AACR 2026, with additional data expected at ASCO 2026, while the Gilead-partnered GS-0321 Phase 1 trial continues to progress. Financially, Compugen reported $2.2 million in revenue, a net loss of $7.7 million and cash and investments of about $134.9 million as of March 31, 2026, and said its debt-free balance sheet provides a cash runway into 2029, supporting its AI-driven discovery platform and potentially value-creating partnerships offering up to $1 billion in milestones plus royalties.
The most recent analyst rating on (CGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Outperform.
The score is driven primarily by the 2025 financial turnaround (profitability and cash generation with low leverage) and a constructive earnings-call outlook (extended runway and validated partnerships). Technicals support the uptrend but are somewhat overextended, and valuation appears optically low but is tempered by the lumpy, partner-driven nature of earnings.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapies, leveraging its Unigen AI/ML-powered computational discovery platform to identify novel drug targets. Its pipeline includes four clinical-stage programs—COM701, COM902, rilvegostomig and GS-0321—targeting solid tumors and immune pathways, with shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
The company collaborates with AstraZeneca on the PD-1/TIGIT bispecific antibody rilvegostomig, now in multiple Phase 3, Phase 2 and Phase 1 trials, and with Gilead on GS-0321, a high-affinity antibody blocking IL-18BP/IL-18 interaction, while also advancing early-stage research programs designed to enhance anti-cancer immunity.
Average Trading Volume: 415,944
Technical Sentiment Signal: Buy
Current Market Cap: $260M
For detailed information about CGEN stock, go to TipRanks’ Stock Analysis page.